Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy

Shuguo Zheng, MD

Status: Unknown

Conditions: Liver Tumor

Treatments: Procedure: Laparoscopic ALPPS

Study type: Observational

Funder types: Other

Identifiers

NCT02203409

SWHZSG005

30972948 (Other Grant/Funding Number)

Details and patient eligibility

About

The purpose of this research is evaluate the results with laparoscopic ALPPS procedure in a single center. The validity, feasibility and limitations were assessed objectively through our clinical prospective study.The investigators expect laparoscopic ALPPS is safe, effective and feasible.

Full description

Background: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a breakthrough in the field of hepatobiliary surgery in recent years，which stimulates the remnant liver volume(RLV) grew by 74%-87.2% in 9 to 13 days。The published literature reported that the two stages of ALPPS are the conventional laparotomy surgery，Patients need to undergo the injury of two open operations in a short time. The incidence of postoperative complications and mortality rate is as high as 53% -73% and 12%-27%.The aim of this study was to evaluate the results with laparoscopic ALPPS procedure in a single center, with special emphasis in validity, feasibility and limitations.

Results:

Clinical data include: operation time, intraoperative blood loss, volume of blood transfusion, complications and mortality, postoperative liver function, long-term curative effect and survival time were collected and analysed.

Statistical method:groups t-test ，univariate/multivariate analysis, logistic regression analysis, mixed linear regression, Cox survival analysis ，Kaplan-Meier survival analysis，Log-rank survival curves were used.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with marginally resectable or primarily non-resectable locally advanced liver tumors
• Insufficient future liver remnant (FLR) either in volume or quality

Exclusion criteria

• Unresectable liver metastases in the future liver remnant or unresectable extrahepatic metastases
• Severe portal hypertension
• High anesthesiological risk
• Unresectable primary tumor

Trial design

30 participants in 1 patient group

Laparoscopic ALPPS group

Description:

Patients with small future liver remnant who are operated with the "Associating Liver Partition and Portal vein ligation for Staged hepatectomy" approach

Treatment:

Procedure: Laparoscopic ALPPS